## 2024 Current Fiscal Year Report: National Cancer Institute Special Emphasis Panel

Report Run Date: 04/25/2024 10:57:38 PM

1. Department or Agency 2. Fiscal Year

Department of Health and Human

Services

2024

3b. GSA
3. Committee or Subcommittee

Committee No.

14c.

National Cancer Institute Special

**Emphasis Panel** 

85

4. Is this New During 5. Current 6. Expected 7. Expected

Fiscal Year? Charter Renewal Date Term Date

No 12/05/1967

8a. Was Terminated During 8b. Specific 8c. Actual Termination Term Date

iscalYear? Authority

No

9. Agency 10b.

Recommendation for Next Req to Terminate?

| Continue of the c

Continue Not Applicable Not Applicable

11. Establishment Authority Authorized by Law

12. Specific 13. 14.

Establishment Effective Commitee Presidential?

Authority Date Type

42 U.S.C. 284(c)(3) 11/04/1988 Continuing No

15. Description of Committee Special Emphasis Panel

16a. Total

No Reports for this FiscalYear

Reports

17a.

0 17b. Closed 0 17c. Partially Closed 0 Other Activities 0 17d. Total 0 Open

**Meetings and Dates** 

No Meetings

**Current Next** 

FY FY

18a(1). Personnel Pmts to Non-Federal Members	\$0.00\$0.00
18a(2). Personnel Pmts to Federal Members	\$0.00\$0.00
18a(3). Personnel Pmts to Federal Staff	\$0.00\$0.00
18a(4). Personnel Pmts to Non-Member Consultants	\$0.00\$0.00
18b(1). Travel and Per Diem to Non-Federal Members	\$0.00\$0.00
18b(2). Travel and Per Diem to Federal Members	\$0.00\$0.00
18b(3). Travel and Per Diem to Federal Staff	\$0.00\$0.00
18b(4). Travel and Per Diem to Non-member Consultants	\$0.00\$0.00
18c. Other(rents,user charges, graphics, printing, mail, etc.)	\$0.00\$0.00
18d. Total	\$0.00\$0.00
19. Federal Staff Support Years (FTE)	0.00 0.00

## 20a. How does the Committee accomplish its purpose?

Special Emphasis Panels (SEPs) are composed of recognized biomedical-related and/or behavioral research authorities who represent the forefront of research and technical knowledge and who provide first-level merit review of highly scientific and technical research grant applications and/or contract proposals in the fields relating to basic and clinical sciences, and applied research and development of programs of special relevance to the NCI. The members and chairs are selected as needed for review of specific applications and contract proposals. The preclinical and clinical discovery and development program Panels, managed by the Division of Cancer Treatment and Diagnosis (DCTD), also evaluates proposals for

support to make available to the research community, on a competitive basis, contract resources for the preclinical development of drugs, biologics, clinical assays, and other developmental programs that would ultimately benefit the advancement of clinical studies. Furthermore, the Panel will provide input to NCI on scientific prioritization of National Clinical Trials Network (NCTN) concepts across diseases guided by a set of criteria when there are insufficient resources to support trials for all NCTN Scientific Steering Committee approved concepts. In FY 2023, 2,252 peer reviewers served on various SEPs. Members selected are experts in the various fields of biomedical research. The SEP evaluates applications for their scientific and technical merit and inform the Institute to make funding decisions. The approaches taken during the review process go beyond the traditional review paradigm-special effort is taken to orient SEP members on the intent of the Institute in issuing the call for applications/proposals and about the approach to be used while reviewing the applications/proposals. Additional attention has been given to the use of information technology and the digitization of information, which reduced costs and enabled the procedures for reviewers to be more effective and efficient throughout the entire peer review process. The Special Emphasis Panels will continue to provide quality peer review for the special initiatives of the Institute. In FY 2023, the SEPs reviewed 3,355 grant applications requesting \$1,561,785,322 in direct costs for the first year and a total of 109 contract proposals were also reviewed.

# 20b. How does the Committee balance its membership?

These committees have a fluid membership, with

members designated to serve for individual meetings rather than formally appointed for fixed terms of service. The reviewers for each meeting are selected to evaluate grant applications and/or contract proposals for a specific, perhaps narrow, expertise area. Participants for each meeting are assembled to most efficiently cover the number and breadth of applications and contracts requiring review. Additionally, staff pays close attention to ensure a diverse and balanced committee membership with the appropriate expertise.

## 20c. How frequent and relevant are the Committee Meetings?

The National Cancer Institute Special Emphasis Panel held 143 advisory committee meetings during this period. Other work group dates include: 2/6-8/2023; 3/31/2023 (5 meetings held on the same day).

## 20d. Why can't the advice or information this committee provides be obtained elsewhere?

This committee is composed of recognized biomedical-related and behavioral research authorities who represent the forefront of research and technical knowledge and who provide first-level merit review of highly scientific and technical research grant applications and contract proposals. These evaluations and recommendations cannot be obtained from other sources because the specialized complex nature of the proposals requires a unique balance and breadth of expertise not available from other established sources.

# 20e. Why is it necessary to close and/or partially closed committee meetings?

The meetings of the National Cancer Institute

Special Emphasis Panel were closed to the public for the review of contract proposals and grant applications. Sections 552b(c)(4) and 552b(c)(6) of the Government in the Sunshine Act permit the closing of meetings where discussions could reveal confidential trade secrets or commercial property such as patentable material and personal information, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

#### 21. Remarks

The DFO and Committee Decision Maker positions are held by the same individual because of the assignment of responsibilities within the Institute. Members: The members of this Special Emphasis Panel (SEP) do not have standing appointments and serve on an as needed basis for meetings throughout the fiscal year. Therefore, the Members list reflects meeting dates, not appointment start and end dates. While only one meeting date is listed as an appointment start and end date, a member may have attended several meetings, either as a chairperson, co-chair, or as a member, throughout the fiscal year. As a result, the Members list, including the number of chairs, may not align or directly match to specific meeting dates. Meeting rosters, including members' affiliations and zip codes are available online at https://public.era.nih.gov/pubroster/. Reports: This committee did not produce any public reports. The following are not duplicate records: Dr. Jiyoung Lee (Georgetown University) and Dr. Ji-Young Lee (University of Connecticut).

### **Designated Federal Officer**

Shamala K. Srinivas Associate Director, Office of Referral, Review and Program Coordination

#### **Narrative Description**

NIH's mission is to seek fundamental knowledge about the nature and behavior of living systems and the application of that knowledge to enhance health, lengthen life, and reduce illness and disability. NIH works toward that mission by supporting the research of non-Federal scientists in universities, medical schools, hospitals, and research institutions throughout the country and abroad. Section 492 of the PHS Act states that The Secretary...shall by regulation require appropriate technical and scientific peer review of -- (A) applications...; and (B) biomedical and behavioral research and development contracts... The National Cancer Institute (NCI) is a component of the National Institutes of Health (NIH), one of eight agencies that compose the Public Health Service (PHS) in the Department of Health and Human Services (DHHS). The National Cancer Institute coordinates the National Cancer Program, which conducts and supports research, training, health information dissemination, and other programs with respect to the cause, diagnosis, prevention, and treatment of cancer, rehabilitation from cancer, and the continuing care of cancer patients and the families of cancer patients. Each Special Emphasis Panel (SEP) advises the Director, National Cancer Institute and the Director, Division of Extramural Activities, NCI, on the scientific merit of research grant and cooperative agreement applications, contract proposals in basic and clinical sciences, and applied research and development programs especially relevant to the National Cancer Institute. The preclinical and clinical discovery and development program panels, managed by the Division of Cancer Treatment and Diagnosis (DCTD), also evaluates proposals for support to make available to the research community, on a competitive basis, contract resources for the preclinical development of drugs, biologics, clinical assays, and other developmental programs that would ultimately benefit the advancement of clinical studies. Furthermore, the panel will provide input to NCI on scientific prioritization of National Clinical Trials Network (NCTN) concepts across diseases guided by a set of criteria when there are insufficient resources to support trials for all

NCTN Scientific Steering Committee approved concepts. The members and chairs of a SEP are selected as needed for peer review of applications, proposals, or proposed solicitations. Members selected are authorities in the various fields of biomedical research. In FY23, 2,252 reviewers served on various SEPs. SEPs primarily serve to review grant applications or contract proposals for their scientific and technical merit and inform the National Cancer Advisory Board for a second level review for the Institute to make funding decisions. The system works well and allows the Institute to develop novel and innovative approaches to stimulate scientific inquiry pertaining to cancer research. The approaches taken during the peer review process go beyond the traditional review paradigm; special effort is taken to orient the SEP members on the intent of the Institute in issuing the call for applications and about the approach to be used while reviewing the applications or proposals. This method produces an efficient review process for the Institute. The SEP will continue to provide quality peer review for the special initiatives of the Institute. Additionally, use of information technology and the digitization of information to reduce costs is used to make the entire process effective and efficient. Further evidence that the SEPs are meeting their mission is evident by the overwhelmingly positive response from the program directors who attend the review sessions. Management remains vigilant during peer review activities—from the selection of peer reviewers to the preparation of the final reports. Review staff are vigilant to conflicts of interest among reviewers and other issues that could compromise the quality of the review process. Frequent interactions of the Chiefs of the four review branches: Research Programs Review Branch (RPRB), Resources and Training Review Branch (RTRB), Research Technology and Contracts Review Branch (RTCRB), and Special Review Branch (SRB) keep the peer review process uniform across various SEPs. The reviewers are highly satisfied with how the review process functions in a SEP setting as demonstrated by positive feedback from peer reviewers at the conclusion of meetings, both in written evaluations and in verbal comments to scientific review officers and staff assistants. Additionally, staff assistants and scientific review officers meet regularly to evaluate the outcome of each meeting and to suggest improvements. Various steps have been taken to improve the

efficiency of the peer review process. Review staff uses digital images of grant applications from IMPAC II and reviewers use the Internet Assisted Review application within the NIH Commons site to access grant applications and other review related materials, on the web. Not only does such an approach save tax dollars, it also helps address regulatory compliance more efficiently and effectively. Orientation teleconferences are regularly used so that the review staff can explain the review process and program staff can explain the intent of the initiative whose applications are to be reviewed. In addition, the orientation teleconferences are digitally recorded so that the discussions are available for those reviewers who may not have been able to participate in the orientation. Use of this approach defines and focuses the review process. In FY23, the National Cancer Institute Special Emphasis Panel held 143 meetings, reviewing a total of 3,355 grant applications requesting \$1,561,785,322.00 in direct costs for the first year and a total of 109 contract proposals were also reviewed.

## What are the most significant program outcomes associated with this committee?

	Checked if Applies	
Improvements to health or safety		
Trust in government		
Major policy changes		
Advance in scientific research		✓
Effective grant making		✓
Improved service delivery		
Increased customer satisfaction		
Implementation of laws or regulatory		
requirements		
Other		

#### **Outcome Comments**

N/A

What are the cost savings associated with this committee?

Checked if Applies

None	✓
Unable to Determine	
Under \$100,000	
\$100,000 - \$500,000	
\$500,001 - \$1,000,000	
\$1,000,001 - \$5,000,000	
\$5,000,001 - \$10,000,000	
Over \$10,000,000	
Cost Savings Other	

### **Cost Savings Comments**

NIH supported basic and clinical research accomplishments often take years to unfold into new diagnostic tests and new ways to treat and prevent diseases.

What is the approximate <u>Number</u> of recommendations produced by this committee for the life of the committee?

62,369

#### **Number of Recommendations Comments**

**Grant Review** 

What is the approximate <u>Percentage</u> of these recommendations that have been or will be <u>Fully</u> implemented by the agency?

0%

### % of Recommendations Fully Implemented Comments

Information on the research funded by NIH is available through the RePORT (Research Portfolio Online Reporting Tool) website. RePORT provides access to reports, data, and analyses of NIH research activities that advance the mission of the NIH, including information on NIH expenditures, strategic plans, reports on NIH funding, and reports on the organization and people involved in NIH research and research training. The RePORT website is located at http://report.nih.gov.

What is the approximate <u>Percentage</u> of these recommendations that have been or will be <u>Partially</u> implemented by the agency?

0%

## % of Recommendations Partially Implemented Comments

Information on the research funded by NIH is available through the RePORT (Research

Portfolio Online Reporting Tool) website. RePORT provides access to reports, data, and analyses of NIH research activities that advance the mission of the NIH, including information on NIH expenditures, strategic plans, reports on NIH funding, and reports on the organization and people involved in NIH research and research training. The RePORT website is located at http://report.nih.gov.

Does the agency provide the committee with feedback regarding actions taken to				
implement recommendations or advice offer	ered?			
Yes No Not Applicable				
Agency Feedback Comments				
Information resulting from closed initial peer re	eview meetings is subject to the Freedom of			
Information Act. The public can view informati	on on research projects funded by NIH on			
the RePORT (Research Portfolio Online Repo	orting Tool) website located at			
http://report.nih.gov.				
What other actions has the agency taken a	s a result of the committee's advice or			
recommendation?				
	Checked if Applies			
Reorganized Priorities				
Reallocated resources				
Issued new regulation				
Proposed legislation				
Approved grants or other payments	<b>✓</b>			

#### **Action Comments**

Other

An action of approved or recommended for grants receiving initial peer review by this committee does not infer that the grant will be or has been funded. Research grant applications submitted to NIH must go through a two-step review process that includes the initial peer review for scientific and technical merit and a second step of review and approval by a National Advisory Council for program relevance. In addition, prior to an award or funding being made, NIH staff must conduct an administrative review for a number of other considerations. These include alignment with NIH's funding principles, review of the project budget, assessment of the applicant's management systems, determination of applicant eligibility, and compliance with public policy requirements. After all these steps have been completed, NIH officials make funding decisions on individual grant applications.

### Is the Committee engaged in the review of applications for grants?

Yes

What is the estimated **Number** of grants reviewed for approval

What is the estimated **Number** of grants recommended for 3,355

approval 3,355

What is the estimated **Dollar Value** of grants recommended for approval

\$1,561,785,322

#### **Grant Review Comments**

**Grant Review** 

## How is access provided to the information for the Committee's documentation?

	Checked if Applies
Contact DFO	✓
Online Agency Web Site	✓
Online Committee Web Site	✓
Online GSA FACA Web Site	<b>√</b>
Publications	✓
Other	✓

#### **Access Comments**

Information on the SEP can be found at the NCI Division of Extramural Activities: Advisory Boards, Committees and Review Groups website at

http://deainfo.nci.nih.gov/advisory/sep/sep.htm. Each NCI FACA committee's information is listed on this site. Information listed includes the committee's charter and rosters.